Hybridoma technology : The birth of monoclonal antibody

Biotechnology
1

Hybridoma technology is a laboratory method used to produce monoclonal antibodies (mAbs) in large quantities. These antibodies are highly specific and bind to only one particular antigen (target). This technique was developed by Georges Köhler and César Milstein in 1975, for which they received the Nobel Prize.

What is the Basic Idea?

  • B-lymphocytes (B-cells) produce antibodies, but they have a short life span.

  • Myeloma cells (cancer cells of plasma origin) can divide continuously but do not produce antibodies.

Hybridoma technology combines these two cells to create a hybrid cell (hybridoma) that:

  • Lives indefinitely (like myeloma cells)

  • Produces specific antibodies (like B-cells)

Steps of Hybridoma Technology

Immunization

  • A laboratory animal (usually a mouse) is injected with a specific antigen.

  • The immune system produces B-cells that generate antibodies against that antigen.

Isolation of B-cells

  • After sufficient immune response, spleen cells (rich in B-cells) are collected from the mouse.

Fusion

  • B-cells are fused with myeloma cells using a chemical agent like PEG (Polyethylene glycol).

  • This forms hybrid cells called hybridomas.

Selection (HAT Medium)

  • Cells are grown in HAT medium (Hypoxanthine-Aminopterin-Thymidine).

  • Only hybridoma cells survive in this medium.

  • Unfused myeloma and B-cells die.

Screening

  • Hybridomas producing the desired antibody are identified using tests like ELISA.

Cloning

  • Selected hybridoma cells are cloned to ensure monoclonality.

  • This ensures production of a single type of antibody.

Mass Production

  • Hybridoma cells are cultured in bioreactors to produce large amounts of monoclonal antibodies.

Applications of Hybridoma Technology

:check_mark: Cancer diagnosis and treatment
:check_mark: Infectious disease detection
:check_mark: Autoimmune disease testing
:check_mark: Pregnancy tests (hCG detection)
:check_mark: Therapeutic antibodies (e.g., Rituximab, Trastuzumab)

Advantages

  • Highly specific antibodies

  • Large-scale production

  • Consistent quality

  • Used in diagnostics and therapy

Limitations

  • Time-consuming process

  • Expensive

  • Mouse-derived antibodies may cause immune reactions in humans

  • Requires animal use

Importance in Cancer Therapy

Monoclonal antibodies produced by hybridoma technology:

  • Target cancer cell surface markers

  • Block tumor growth

  • Deliver drugs directly to tumor cells

  • Stimulate immune response

unnamed (1)
unnamed (1)1920×1072 378 KB

MBH/PS

2 Likes
2

A beautifully articulated reminder of how hybridoma technology revolutionized modern medicine, laying the foundation for targeted diagnostics and therapeutics.

1 Like
3

That seems to be such a unique and amazing approach. The developments in science do seem impossible at one point, but when they are finally done, the quest for further development begins. Maybe this can be used for patients with suppressed immunity
amazingly explained the topic

1 Like
4

Hybridoma technology truly revolutionized antibody production by merging the immortality of myeloma cells with the specificity of B-cells. I see it as the foundation for today’s therapeutic antibodies used in cancer and autoimmune diseases. While challenges like immunogenicity exist, advances such as humanized antibodies and recombinant methods have built on this platform. It remains a technique that bridged basic immunology with modern biopharmaceuticals.

1 Like